ABSTRACT
The goal of the present study was to design a vaccine that would provide universal protection against infection of humans with diverse influenza A viruses. Accordingly, protein sequences from influenza A virus strains currently in circulation (H1N1, H3N2), agents of past pandemics (H1N1, H2N2, H3N2) and zoonotic infections of man (H1N1, H5N1, H7N2, H7N3, H7N7, H9N2) were evaluated for the presence of amino acid sequences, motifs, that are predicted to mediate peptide epitope binding with high affinity to the most frequent HLA-DR allelic products. Peptides conserved among diverse influenza strains were then synthesized, evaluated for binding to purified HLA-DR molecules and for their capacity to induce influenza-specific immune recall responses using human donor peripheral blood mononuclear cells (PBMC). Accordingly, 20 epitopes were selected for further investigation based on their conservancy among diverse influenza strains, predicted population coverage in diverse ethnic groups and capacity to recall influenza-specific responses. A DNA plasmid encoding the epitopes was constructed using amino acid spacers between epitopes to promote optimum processing and presentation. Immunogenicity of the DNA vaccine was measured using HLA-DR4 transgenic mice and the TriGrid in vivo electroporation device. Vaccination resulted in peptide-specific immune responses, augmented HA-specific antibody responses and protection of HLA-DR4 transgenic mice from lethal PR8 influenza virus challenge. These studies demonstrate the utility of this vaccine format and the contribution of CD4(+) T cell responses to protection against influenza infection.
Subject(s)
Epitopes, T-Lymphocyte/immunology , HLA-DR Antigens/immunology , Influenza A virus/immunology , Influenza Vaccines/immunology , Vaccines, DNA/immunology , Animals , Antibodies, Viral/blood , Cells, Cultured , Conserved Sequence/genetics , Conserved Sequence/immunology , Epitopes, T-Lymphocyte/genetics , HLA-DR Antigens/metabolism , Humans , Influenza A virus/genetics , Influenza Vaccines/genetics , Influenza, Human/prevention & control , Leukocytes, Mononuclear/immunology , Mice , Mice, Transgenic , Peptides/immunology , Peptides/metabolism , Protein Binding , Survival Analysis , Vaccines, DNA/geneticsABSTRACT
The cellular immune system is characterized by flexibility with respect to epitope recognition at the level of peptide binding to HLA molecules and HLA-peptide complexes to T-cell receptors (TCRs). For epitopes recognized by cytotoxic T-lymphocytes (CTLs), amino acid substitutions at different positions have varying impact on recognition. By analyzing the frequencies of specific amino acid substitutions at each position in conjunction with HLA-peptide binding and immune-response data, we have developed new methods to predict cross-reactive recognition of epitope variants by CTLs. We derived position-specific substitution matrices (EPSSMs) through the analysis of known HLA ligands and achieved relatively accurate prediction of detrimental and tolerated amino acid substitutions. Initial analysis of amino acid substitutions in CTL epitopes with degenerate recognition showed strong position-specific preferences. This first systematic analysis further suggested that spatial constraint may be the major molecular factor determining the degenerate epitope recognition. As the data cumulates, we anticipate that eventually EPSSMs will be available for prediction of degenerate T-cell epitope recognition.
Subject(s)
Amino Acid Substitution , Epitopes, T-Lymphocyte/genetics , HIV-1/immunology , T-Lymphocytes, Cytotoxic/immunology , AIDS Vaccines/immunology , Cross Reactions , Epitopes, T-Lymphocyte/immunology , Genetic Variation , HIV-1/genetics , HLA Antigens/genetics , HLA Antigens/metabolism , HLA-A2 Antigen/genetics , HLA-A2 Antigen/metabolism , Humans , Ligands , Predictive Value of TestsABSTRACT
Protein sequences from multiple hepatitis B virus (HBV) isolates were analyzed for the presence of amino acid motifs characteristic of cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes with the goal of identifying conserved epitopes suitable for use in a therapeutic vaccine. Specifically, sequences bearing HLA-A1, -A2, -A3, -A24, -B7, and -DR supertype binding motifs were identified, synthesized as peptides, and tested for binding to soluble HLA. The immunogenicity of peptides that bound with moderate to high affinity subsequently was assessed using HLA transgenic mice (CTL) and HLA cross-reacting H-2(bxd) (BALB/c x C57BL/6J) mice (HTL). Through this process, 30 CTL and 16 HTL epitopes were selected as a set that would be the most useful for vaccine design, based on epitope conservation among HBV sequences and HLA-based predicted population coverage in diverse ethnic groups. A plasmid DNA-based vaccine encoding the epitopes as a single gene product, with each epitope separated by spacer residues to enhance appropriate epitope processing, was designed. Immunogenicity testing in mice demonstrated the induction of multiple CTL and HTL responses. Furthermore, as a complementary approach, mass spectrometry allowed the identification of correctly processed and major histocompatibility complex-presented epitopes from human cells transfected with the DNA plasmid. A heterologous prime-boost immunization with the plasmid DNA and a recombinant MVA gave further enhancement of the immune responses. Thus, a multiepitope therapeutic vaccine candidate capable of stimulating those cellular immune responses thought to be essential for controlling and clearing HBV infection was successfully designed and evaluated in vitro and in HLA transgenic mice.
Subject(s)
Epitopes, T-Lymphocyte/genetics , Epitopes, T-Lymphocyte/immunology , Hepatitis B Vaccines/genetics , Hepatitis B Vaccines/immunology , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/immunology , Immunotherapy/methods , Animals , Female , Hepatitis B Vaccines/therapeutic use , Hepatitis B virus/immunology , Immunization, Secondary , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Plasmids/genetics , Plasmids/immunology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Helper-Inducer/immunology , Vaccines, DNA/genetics , Vaccines, DNA/immunology , Vaccinia virus/genetics , Viral Vaccines/genetics , Viral Vaccines/immunologyABSTRACT
Epitope-based vaccines designed to induce CTL responses specific for HIV-1 are being developed as a means for addressing vaccine potency and viral heterogeneity. We identified a set of 21 HLA-A2, HLA-A3, and HLA-B7 restricted supertype epitopes from conserved regions of HIV-1 to develop such a vaccine. Based on peptide-binding studies and phenotypic frequencies of HLA-A2, HLA-A3, and HLA-B7 allelic variants, these epitopes are predicted to be immunogenic in greater than 85% of individuals. Immunological recognition of all but one of the vaccine candidate epitopes was demonstrated by IFN-gamma ELISPOT assays in PBMC from HIV-1-infected subjects. The HLA supertypes of the subjects was a very strong predictor of epitope-specific responses, but some subjects responded to epitopes outside of the predicted HLA type. A DNA plasmid vaccine, EP HIV-1090, was designed to express the 21 CTL epitopes as a single Ag and tested for immunogenicity using HLA transgenic mice. Immunization of HLA transgenic mice with this vaccine was sufficient to induce CTL responses to multiple HIV-1 epitopes, comparable in magnitude to those induced by immunization with peptides. The CTL induced by the vaccine recognized target cells pulsed with peptide or cells transfected with HIV-1 env or gag genes. There was no indication of immunodominance, as the vaccine induced CTL responses specific for multiple epitopes in individual mice. These data indicate that the EP HIV-1090 DNA vaccine may be suitable for inducing relevant HIV-1-specific CTL responses in humans.
Subject(s)
AIDS Vaccines/immunology , Conserved Sequence/immunology , Cytotoxicity Tests, Immunologic/methods , Epitopes, T-Lymphocyte/immunology , HIV-1/immunology , T-Lymphocytes, Cytotoxic/immunology , Vaccines, DNA/immunology , AIDS Vaccines/administration & dosage , AIDS Vaccines/chemical synthesis , Adult , Amino Acid Motifs/immunology , Animals , Cell Line, Transformed , Drug Evaluation, Preclinical , Enzyme-Linked Immunosorbent Assay , Epitopes, T-Lymphocyte/isolation & purification , HIV Infections/immunology , HIV-1/isolation & purification , HLA-A2 Antigen/genetics , HLA-A2 Antigen/immunology , HLA-A3 Antigen/genetics , HLA-A3 Antigen/immunology , HLA-B7 Antigen/genetics , HLA-B7 Antigen/immunology , Histocompatibility Testing , Humans , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/virology , Mice , Mice, Transgenic , Predictive Value of Tests , Superantigens/immunology , T-Lymphocytes, Cytotoxic/virology , Vaccines, DNA/administration & dosage , Vaccines, DNA/chemical synthesisABSTRACT
HLA class I molecules can be classified into supertypes associated with overlapping peptide-binding motifs and repertoires. Herein, overlaps in peptide-binding and T-cell recognition repertoires were demonstrated between mouse and human molecules. Since rodent and primate lineages separated before the current allelic variation of mouse and human class I molecules, these data demonstrate that supertypic specificities originated by convergent evolution. Phylogenetic and structural analyses demonstrated that convergent evolution also occurs amongst primates and within the human species, resulting from the selection of different pocket structures having similar specificity or independent repeated selection of the same pocket structure.
Subject(s)
Evolution, Molecular , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/metabolism , Amino Acid Motifs , Amino Acid Sequence , Animals , Binding Sites , H-2 Antigens/genetics , H-2 Antigens/metabolism , HLA-A Antigens/genetics , HLA-A Antigens/metabolism , HLA-B7 Antigen/genetics , HLA-B7 Antigen/metabolism , Histocompatibility Antigen H-2D , Humans , Mice , Mice, Inbred BALB C , Models, Molecular , Peptides/immunology , Peptides/metabolism , Phylogeny , Protein Binding , Species SpecificityABSTRACT
Four HLA-DR-restricted HIV-derived Th lymphocyte (HTL) epitopes cross-reactive with the murine I-A(b) class II molecule were used to evaluate different vaccine design strategies to simultaneously induce multiple HTL responses. All four epitopes were immunogenic in H-2(b) mice, demonstrating the feasibility of murine models to evaluate epitope-based vaccines destined for human use. Immunization with a pool of peptides induced responses against all four epitopes; illustrating immunodominance does not prevent the induction of balanced multispecific responses. When different delivery systems were evaluated, a multiple Ag peptide construct was found to be less efficient than a linear polypeptide encompassing all four epitopes. Further characterization of linear polypeptide revealed that the sequential arrangement of the epitopes created a junctional epitope with high affinity class II binding. Disruption of this junctional epitope through the introduction of a GPGPG spacer restored the immunogenicity against all four epitopes. Finally, we demonstrate that a GPGPG spacer construct can be used to induce HTL responses by either polypeptide or DNA immunization, highlighting the flexibility of the approach.